If 350 million shares are AUTHORIZED, that does not mean
If 350 million shares are AUTHORIZED, that does not mean that the company will SELL all of them.
It's a powerful negotiating point for a company to have a bunch of shares they can use for fundraising.
The more likely scenario is that they will just let the ones they don't need for payroll and things like paying for lawyers just sit there. You know, "F U prospective partner, give us a good deal or we'll just fund ourselves."
It would be extremely unusual for the company actually to release that many shares in a short period of time -- unless they are using them to acquire some other company, or something major like that.
2
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Concerns About Cryptocurrency Announcements Prominent economist and market commentator Peter Schiff has urged a Congressional investigation into President Donald Trump's recent foray into cryptocurrency, suggesting that these announcements may involve insider trading and market manipulation. The Key Questions Raised In a recent post on X, Schiff sought answers to several...
Continue Reading
BriaCell Enters MSK’s 2025 Therapeutics Accelerator Program BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, TSX: BCT) is thrilled to share the news of its selection into the Memorial Sloan Kettering Cancer Center (MSK) Therapeutics Accelerator Program for 2025. This prestigious program is designed to fast-track the clinical development of many innovative cancer...
Continue Reading
Understanding Net Asset Value (NAV) in Investment Funds Net Asset Value (NAV) is a crucial metric for evaluating the performance of investment funds, representing the value of a fund's assets minus its liabilities. It's important for investors to keep track of NAV as it aids in making informed decisions regarding their investments. Here, we delve into the recent NAVs of...
Continue Reading
Introduction to DoorDash's Expansion DoorDash (NASDAQ: DASH) has recently unveiled exciting developments regarding its Commerce Platform. This significant enhancement is set to assist restaurants in boosting direct sales while fostering better customer relationships across multiple channels. New Features for Restaurant Success The introduced tools are designed to uplift...
Continue Reading
Positive News for Udenafil in Kidney Disease New updates from Mezzion Pharma Co., Ltd. have come across quite promising. They've reported some favorable results in a preclinical study of udenafil, targeting autosomal dominant polycystic kidney disease (ADPKD). It appears that this PDE5 inhibitor, typically used in aiding cardiovascular issues, now shows potential in...
Continue Reading
